- Home
- ENGN vs INBX Comparison
ENGN vs INBX Comparison
Compare ENGN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- INBX
- Stock Information
- Founded
- ENGN 1999
- INBX 2010
- Country
- ENGN Canada
- INBX United States
- Employees
- ENGN N/A
- INBX N/A
- Industry
- ENGN
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- INBX Health Care
- Exchange
- ENGN Nasdaq
- INBX Nasdaq
- Market Cap
- ENGN 321.5M
- INBX 345.8M
- IPO Year
- ENGN N/A
- INBX 2020
- Fundamental
- Price
- ENGN $5.97
- INBX $27.19
- Analyst Decision
- ENGN Buy
- INBX Hold
- Analyst Count
- ENGN 8
- INBX 2
- Target Price
- ENGN $21.50
- INBX N/A
- AVG Volume (30 Days)
- ENGN 217.5K
- INBX 111.3K
- Earning Date
- ENGN 09-11-2025
- INBX 11-13-2025
- Dividend Yield
- ENGN N/A
- INBX N/A
- EPS Growth
- ENGN N/A
- INBX N/A
- EPS
- ENGN N/A
- INBX N/A
- Revenue
- ENGN N/A
- INBX $1,400,000.00
- Revenue This Year
- ENGN N/A
- INBX N/A
- Revenue Next Year
- ENGN N/A
- INBX N/A
- P/E Ratio
- ENGN N/A
- INBX N/A
- Revenue Growth
- ENGN N/A
- INBX N/A
- 52 Week Low
- ENGN $2.65
- INBX $10.81
- 52 Week High
- ENGN $11.00
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- ENGN 72.82
- INBX 56.51
- Support Level
- ENGN $5.52
- INBX $27.51
- Resistance Level
- ENGN $6.54
- INBX $28.86
- Average True Range (ATR)
- ENGN 0.53
- INBX 1.49
- MACD
- ENGN 0.12
- INBX -0.19
- Stochastic Oscillator
- ENGN 76.64
- INBX 48.91
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.